Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Active and recent NIH-funded research on Lafora Disease. Data from NIH RePORTER, last 36 months.
Lafora Disease has emerging NIH research funding with 3 grants totaling $3.2M.
1 new grant started in the last 12 months.
NIH fiscal year (Oct–Sep)
Cross-referencing NIH grants against published research and clinical trials to identify funding-evidence gaps for Lafora Disease. Strongest funded area: Translational / Drug Development. Largest gap: Epidemiology / Natural History.
7 publications in Diagnostic / Biomarker but no NIH-funded grants found in Biomarker / Diagnostics for Lafora disease. Existing research activity suggests this may be a viable area for grant applications.
15 publications in Case Report / Case Series but no NIH-funded grants found in Epidemiology / Natural History for Lafora disease. Existing research activity suggests this may be a viable area for grant applications.
7 publications in Clinical Trial Publication but no NIH-funded grants found in Clinical Research for Lafora disease. Existing research activity suggests this may be a viable area for grant applications.
7 publications in Epidemiology / Natural History but no NIH-funded grants found in Epidemiology / Natural History for Lafora disease. Existing research activity suggests this may be a viable area for grant applications.
These grants mention Lafora Disease as part of broader research but are not primarily focused on this disease. They are not included in the funding totals above.